SVB Wealth LLC lifted its stake in Haleon plc (NYSE:HLN – Get Rating) by 14.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,019 shares of the company’s stock after buying an additional 2,257 shares during the quarter. SVB Wealth LLC’s holdings in Haleon were worth $144,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also recently made changes to their positions in the company. CKW Financial Group purchased a new stake in shares of Haleon during the third quarter worth about $26,000. Tompkins Financial Corp purchased a new stake in shares of Haleon during the fourth quarter worth about $31,000. Clearstead Advisors LLC purchased a new stake in shares of Haleon during the third quarter worth about $32,000. Glassman Wealth Services grew its position in shares of Haleon by 1,052.6% during the fourth quarter. Glassman Wealth Services now owns 4,518 shares of the company’s stock worth $36,000 after purchasing an additional 4,126 shares in the last quarter. Finally, CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Haleon during the third quarter worth about $37,000. Institutional investors own 6.67% of the company’s stock.
Haleon Price Performance
Shares of HLN stock opened at $8.26 on Monday. Haleon plc has a 52-week low of $5.59 and a 52-week high of $9.05. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.93 and a quick ratio of 0.62. The stock has a 50 day moving average price of $8.60 and a 200 day moving average price of $8.02.
Haleon Announces Dividend
Wall Street Analyst Weigh In
Several equities analysts have weighed in on HLN shares. Barclays raised their price target on Haleon from GBX 360 ($4.48) to GBX 364 ($4.53) in a report on Tuesday, January 31st. Sanford C. Bernstein started coverage on Haleon in a report on Tuesday, April 4th. They set an “outperform” rating for the company. Investec began coverage on Haleon in a report on Thursday, February 23rd. They set a “sell” rating for the company. Argus upgraded Haleon from a “hold” rating to a “buy” rating in a report on Thursday, April 6th. Finally, Stifel Nicolaus began coverage on Haleon in a report on Wednesday, May 24th. They issued a “hold” rating for the company. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Haleon currently has a consensus rating of “Hold” and a consensus target price of $364.00.
Haleon Profile
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.
Further Reading
- Get a free copy of the StockNews.com research report on Haleon (HLN)
- MarketBeat Week in Review – 5/22 – 5/26
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
Want to see what other hedge funds are holding HLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haleon plc (NYSE:HLN – Get Rating).
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
